FOXO Labs, Inc. is a biotechnology company dedicated to improving human health and life span through the development of cutting-edge technology and product solutions for various industries. For more ...

CEO, David Bailey added, “This launch marks our inaugural Pediatric Plating Platform and underscores our commitment to expanding the platform into the most comprehensive plating portfolio in pediatric ...

Donnelly brings over 35 years of dining and restaurant expertise, including Thrive Restaurant Group, where he was a key principal in the development and execution of the HomeGrown breakfast and lunch ...

The Company will reconvene its Annual General and Special Meeting of shareholders (the “Reconvened Meeting”) on August 22, 2025 at 10:00 a.m. (Eastern Time) to vote on the appointment of EY and the ...

NeuroPace will continue to work with CMS on MS-DRG improvements and other reimbursement related topics. The company remains committed to ensuring that reimbursement policy keeps pace with clinical ...

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, ...

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, ...

We appreciate the continued support from our loyal investors for supporting NEXGEL during this critical period in our history.” Alere Financial Partners, LLC, a division of Cova Capital Partners, LLC ...

ROSELAND, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, ...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024; Dupixent ® global net sales (recorded by Sanofi) increased 22% to $4.34 billion ; EYLEA HD ...

Promising preclinical data for MDNA113 was presented at AACR 2025, highlighting its tumor-targeted design and strong anti-tumor activity in IL-13Rα2–positive tumor models, supporting development ...

The Amended Loan Agreement replaces the prior loan agreement between Oculis and the Lender dated May 29, 2024, and the upsized structure will provide CHF 75.0 million in borrowing capacity (which may ...